REFERENCES
- Washington CB, Flexner C, Sheiner LB, et al. Effect of simultaneous versus staggered dosing on pharmacoki-netic interactions of protease inhibitors. Clin Pharmacol Ther 2003;73:406–416
- Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother Sept 25, 2007. E-pub ahead of print.
- Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self report and electronic moni-toring. Clin Infect Dis. 2001;33:1417–1423.
- McNabb JJ, Nicolau DP, Stoner JA, et al. Patterns of adherence to antiretroviral medications: the value of elec-tronic monitoring. AIDS. 2003;17:1763–1767.
- Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–266.
- Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selec-tive drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005;40:294–300.
- Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentra-tions as a marker. AIDS. 1998;12:2305–2311.
- Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001134: 968–977.
- McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: the value of elec-tronic monitoring. AIDS. 2003;17:1763–1767.
- MacArthur RD, Novak RM, Peng G, et al. A compari-son of three highly active antiretroviral treatment strate-gies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase as initial therapy (CPCRA 058 FIRST study): a long-term randomized trial. Lancet. 2006;368:2125–2135.
- Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure and resistance. AIDS. 2008;22:75–82.
- Gross R, Yip B, Wood E, et al. Boosted protease inhibitors are more forgiving of suboptimal adherence than non-boosted protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO. Abstract K–210.
- Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic sup-pression despite adherence rates below 95%. J Acquir Immune Defic Syndr 2007;45:4–8.
- Bartlett JG. International workshop on management of treat-ment experienced patients. Hopkins HIV Rep. 2002;14:4–5.
- Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001134: 968–977.
- Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.